EyePoint ($EYPT) Stock Hub 2026: What Does LUCIA Have to Show After LUGANO, and Who Bought in August?

01 LUGANO has changed the thesis

EyePoint’s first pivotal wet-AMD study is formally negative on its primary endpoint. LUGANO did not demonstrate prespecified noninferiority in best-corrected visual acuity versus aflibercept in the full analysis set. That result materially increases clinical, regulatory and financing risk because DURAVYU carries most of EyePoint’s forward strategic value.

The study was not devoid of encouraging evidence. EyePoint reported a 42% reduction in treatment burden, two fewer injections on average, favorable anatomical control and a safety profile the company described as favorable. An ad hoc exclusion of nine DURAVYU patients with severe vision losses considered unrelated to wet AMD produced nominal noninferiority at p=0.0096. That sensitivity is potentially informative, but it was not the prespecified primary analysis and cannot be treated as though LUGANO met its endpoint.

02 Formally negative primary result, clinically supportive secondary evidence

The correct interpretation is neither “the drug completely failed” nor “the endpoint was effectively met.” LUGANO missed the prespecified primary endpoint, while several secondary and ad hoc observations still suggest that sustained delivery may reduce treatment burden without an obvious anatomical or safety penalty.

Current research posture: EYPT is now a high-risk evidence-reconciliation story. The clinical utility signal remains alive, but the valuation must reflect a failed primary endpoint, dependence on a second pivotal readout and the possibility that regulators will not accept a package supported by an ad hoc rescue of the first study. Liquidity of $180.5 million at June 30 helps the company reach near-term milestones, while ongoing ATM issuance shows that dilution remains part of the funding strategy.

03 Inside this Stock Hub

1. Company overview and strategic reset
2. What DURAVYU is and how it works
3. What the Phase 2 evidence actually showed
4. LUGANO Phase 3
5. LUCIA Phase 3
6. How to interpret the topline data
7. Catalyst map
8. DME expansion: COMO and CAPRI
9. Manufacturing, IP and economics
10. Legal, regulatory and compliance context
11. Financial position and dilution
12. Ownership, short interest and trading structure
13. Management and launch preparation
14. Competitive landscape
15. Bull, base and bear scenarios
16. Risks and thesis breakers
17. Merlintrader conclusion

04 EyePoint Company Overview: From Sustained-Release Heritage to a DURAVYU-Centered Company

EyePoint, Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company focused on sustained delivery treatments for serious retinal diseases. Its current identity is dominated by DURAVYU, formerly known as EYP-1901, a bioerodible intravitreal insert containing the tyrosine kinase inhibitor vorolanib. The company is evaluating DURAVYU in global pivotal programs for wet age-related macular degeneration and diabetic macular edema.

The corporate history matters because EyePoint is not attempting to enter ophthalmology without delivery experience. Its Durasert family has been used across several approved ocular products and, according to company filings, in tens of thousands of treated eyes. Earlier generations were non-erodible implants. DURAVYU uses the newer Durasert E platform, designed to biodegrade after delivering a very high proportion of its drug payload.

EyePoint also changed its economic profile by transferring U.S. YUTIQ product rights to ANI Pharmaceuticals in 2023. The transaction supplied substantial upfront and installment consideration and sharpened EyePoint’s focus on DURAVYU. The legacy revenue stream is now small: first-quarter 2026 revenue totaled approximately $0.7 million, including only about $0.1 million of royalty income, after the prior SWK royalty arrangement terminated in March 2025. EyePoint therefore retains some supply, licensing and ex-U.S. economics, but it should be valued primarily as a DURAVYU development company rather than as a meaningful commercial royalty business.

What EyePoint already has

• Decades of sustained ocular-delivery development.
• A purpose-built commercial-scale manufacturing facility.
• Completed wet AMD enrollment in two pivotal studies.
• Cash runway extending beyond the first major readouts.

What remains unproven

• Phase 3 efficacy versus on-label aflibercept.
• Commercially compelling injection-burden reduction.
• Regulatory acceptance of the full drug-device package.
• Pricing, reimbursement and real-world adoption.

Why the equity is concentrated

• DURAVYU is the main driver of forward value.
• Revenue is currently minimal relative to operating cost.
• Phase 3 spending and launch preparation consume substantial cash.
• A major setback would likely require strategy and cost resets.

05 What Is DURAVYU?

DURAVYU combines vorolanib, a selective small-molecule tyrosine kinase inhibitor, with EyePoint’s bioerodible Durasert E sustained-delivery technology. The insert is administered intravitreally in an office-based procedure and is designed to release drug in the eye for approximately six months before redosing.

Vorolanib inhibits intracellular signaling associated with VEGF receptors. Company materials also describe activity involving PDGF and IL-6/JAK1 pathways, creating a broader mechanistic proposition than simple extracellular VEGF neutralization. In practical terms, EyePoint is trying to maintain anti-angiogenic control inside the eye for a much longer interval than standard injections while avoiding the need for a surgically implanted refillable reservoir.

The platform design is commercially important. A sustained therapy must satisfy several demands at once: the initial procedure needs to be practical for retinal specialists; the release profile must be consistent; the insert must remain in the intended location; ocular inflammation must remain acceptably low; and the patient must gain a meaningful reduction in treatment burden without sacrificing vision or anatomical control.

06 Phase 2 Evidence: Why EyePoint Advanced Directly Into a Large Pivotal Program

The investment case rests on the belief that Phase 2 data created enough clinical confidence to justify two large, registration-directed trials. The most important evidence comes from DAVIO 2 in previously treated wet AMD patients and VERONA in DME.

DAVIO 2 in wet AMD

DAVIO 2 enrolled 160 previously treated wet AMD patients and compared two DURAVYU doses with aflibercept. EyePoint reported that both DURAVYU dose groups met the study’s primary and secondary endpoints. At the blended weeks 28 and 32 analysis, visual-acuity outcomes were approximately 0.3 to 0.4 letters below the aflibercept control—an extremely small numerical difference in the context of a durability study.

The treatment-burden data drove much of the enthusiasm. EyePoint reported reductions of approximately 85% to 89% in treatment burden, with roughly 64% to 65% of patients remaining supplement-free through six months after a single insert. Retinal thickness remained broadly controlled, with a difference of less than ten microns versus aflibercept at week 32. The company also reported no DURAVYU-related ocular or systemic serious adverse events in the study.

At twelve months, vision remained similar to the aflibercept arm and the anatomical profile continued to support durability. Roughly half of the patients remained supplement-free after one DURAVYU administration. That finding was encouraging, but it should not be overextended: the pivotal program uses planned six-month redosing, and Phase 3 includes a large treatment-naive population that may behave differently from previously controlled patients.

Why Phase 2 does not guarantee Phase 3

The pivotal studies are larger, include mostly treatment-naive patients and use an active comparator under a formal noninferiority design. Treatment-naive wet AMD can produce larger early vision gains with intensive anti-VEGF loading, potentially making it harder for a sustained insert to match the control arm. Rescue-treatment rules, missing data, discontinuations and the distribution of results—not only the mean—can alter the statistical conclusion.

Phase 2 established a credible hypothesis. Phase 3 must prove that the hypothesis survives a more heterogeneous population, more sites, larger operational scale and the exact analysis required for registration.

07 LUGANO Phase 3: What the Topline Result Actually Showed

Topline reported August 17, 2026 · 432 patients enrolled · NCT06668064

LUGANO is a randomized, double-masked, active-controlled Phase 3 trial comparing the 2.7 mg DURAVYU insert on a six-month redosing schedule with aflibercept in wet AMD. The primary analysis blended BCVA measurements at weeks 52 and 56 and tested noninferiority.

Why EyePoint believes the dataset still supports DURAVYU

• An ad hoc analysis excluded nine DURAVYU patients whose losses of at least 15 letters were considered unrelated to wet AMD; that analysis reached nominal noninferiority at p=0.0096.
• DURAVYU reduced treatment burden by 42%, equivalent to two fewer injections on average through week 56.
• Seventy-six percent of patients remained supplement-free through week 32 and 54% through week 56.
• Seventy-nine percent required zero or one supplemental injection through week 56.
• Reported CST differences were small at topline level, and the company described safety as favorable.

What remains unresolved

• Whether the nine severe vision-loss cases were balanced by mechanism, site and timing, and whether exclusion is accepted by regulators.
• The complete confidence interval for the prespecified primary analysis and all planned sensitivity analyses.
• Performance in treatment-naive versus previously treated eyes.
• Detailed rescue-treatment timing, anatomical distributions and ocular adverse-event tables.
• Whether LUCIA independently produces a clean prespecified result.

See EyePoint’s official LUGANO topline announcement.

08 LUCIA Phase 3: Replication Is Now Decisive

Company guidance: Q4 2026 · 475 patients · NCT06683742

LUCIA is the identically designed companion pivotal study and uses the same blended weeks 52 and 56 BCVA noninferiority framework. Before LUGANO, it was the expected replication layer. After LUGANO’s primary-endpoint miss, it becomes the study most likely to determine whether EyePoint can still present a credible wet-AMD registration package.

Investors should focus on whether LUCIA meets the endpoint in its prespecified population without requiring exclusions, the numerical BCVA difference and confidence interval, consistency of rescue-treatment reduction, anatomical control, safety and the treatment-naive subgroup. EyePoint continues to guide LUCIA topline data for Q4 2026.

09 How to Read the Evidence After LUGANO

Why the nine excluded cases matter

The central analytical question is not simply whether those losses were unrelated to wet AMD. Investors need the predefined rules, timing, causes, site concentration, treatment balance and all other sensitivity analyses. An exclusion can reveal a genuine distortion in a dataset, but when it is introduced after the primary analysis, it also increases the risk of a result that is not reproducible.

Why burden reduction still matters

DURAVYU’s value proposition is fewer injections while maintaining acceptable visual and anatomical outcomes. A 42% burden reduction and 79% of patients needing zero or one supplement through week 56 are clinically relevant observations. Their commercial and regulatory value depends on LUCIA confirming efficacy under the prespecified statistical framework.

10 EyePoint Catalyst Map

The sequence is now dominated by evidence clarification and replication.

• Detailed LUGANO presentation: full confidence intervals, sensitivity analyses, causes of severe vision loss, rescue-treatment distributions, subgroups, anatomy and safety.
• LUCIA Phase 3 topline — Q4 2026: the decisive replication readout and the clearest test of whether the wet-AMD registration thesis survives.
• Regulatory interaction: management guidance after the paired data on whether the totality can support an NDA. The previously discussed first-half 2027 filing path should now be viewed as contingent, not assumed.
• COMO and CAPRI in DME: both Phase 3 studies completed enrollment in July 2026; topline data remain anticipated in Q4 2027.
• Financing and runway: cash use, ATM issuance and any change in operating plans following the LUGANO result.
• CMC and manufacturing: continued readiness matters if a viable registration path emerges.

11 Diabetic Macular Edema: COMO and CAPRI Create a Second Franchise Opportunity

Wet AMD is the immediate valuation driver, but DME could determine whether DURAVYU becomes a single-indication product or a broader retina franchise. EyePoint initiated two global pivotal Phase 3 studies—COMO and CAPRI—in early 2026. Each targets approximately 240 patients and uses a six-month redosing strategy.

On July 30, EyePoint reported that both studies were fully enrolled, with more than 480 patients across COMO and CAPRI within five months and ahead of the prior Q3 completion window. Each study is global, randomized and double-masked, compares DURAVYU 2.7 mg with on-label aflibercept 2 mg, and uses a six-month re-dosing schedule. The primary endpoint is the average change in best-corrected visual acuity across Weeks 52 and 56. Topline results remain expected in the fourth quarter of 2027; that timeline is forward-looking and can change.

VERONA Phase 2 evidence

VERONA was a small, 27-patient Phase 2 study, so it should be viewed as hypothesis-generating rather than definitive. EyePoint reported that both DURAVYU doses met the primary endpoint measuring time to first supplemental treatment. In the 2.7 mg group, mean visual acuity improved by approximately 7.1 letters and central subfield thickness improved by roughly 75.9 microns. Approximately 73% of patients were supplement-free through week 24 versus 50% in the control group.

In a supplement-free subgroup analysis, the company reported larger gains in vision and anatomy and a higher proportion of eyes without DME. These findings supported advancement into Phase 3, but the very small sample size makes the upcoming pivotal studies the first reliable test of reproducibility.

Why DME increases strategic value

• Another large anti-VEGF-treated retinal market.
• Potential platform leverage across manufacturing and commercial infrastructure.
• Broader physician familiarity if the wet AMD launch succeeds.
• Multi-pathway TKI mechanism may be particularly relevant to inflammatory components.

Why DME does not remove near-term risk

• Topline data are not expected until 2027.
• The Phase 2 dataset was very small.
• A negative wet AMD result would weaken confidence in the platform.
• Funding both Phase 3 programs materially increases cash burn.

12 Manufacturing, CMC, Intellectual Property and Product Economics

Northbridge manufacturing facility

EyePoint has invested in a roughly 41,000-square-foot cGMP manufacturing facility in Northbridge, Massachusetts. The company reported completion of registration batches for DURAVYU by early 2026 and continued technology transfer and commercial preparation. This is a strategic asset because sustained-release ocular products combine drug and delivery-device considerations, making process consistency and inspection readiness central to approvability.

Owning manufacturing capacity can improve control over quality and commercial supply. It also creates fixed costs, validation responsibilities and operational concentration. EyePoint’s filings identify dependence on specific manufacturing locations and sole-source or limited-source inputs, including vorolanib active ingredient. A positive clinical result would therefore move CMC from a secondary diligence item to one of the most important remaining regulatory risks.

Historical FDA warning letter at the Watertown facility

Manufacturing diligence must also include EyePoint’s separate Watertown facility history. After a February 2024 inspection related specifically to YUTIQ manufacturing, the FDA classified the facility as Official Action Indicated and issued a warning letter on July 12, 2024 citing alleged current good manufacturing practice deficiencies. EyePoint disclosed corrective and preventive actions, follow-up communications during 2025 and an expectation that its final response confirming completion of remediation would be submitted during the first half of 2026.

The company stated in its 2025 Form 10-K that, based on the information then available, it did not believe DURAVYU or its other development programs were affected by that regulatory action. Watertown and Northbridge are distinct facilities and the warning letter concerned YUTIQ, so it would be inaccurate to describe it as a DURAVYU finding. It remains relevant, however, because FDA confidence in company-wide quality systems, investigation procedures, process controls and sustainable compliance can influence inspection risk and investor perception.

Licensing economics for vorolanib

EyePoint licensed vorolanib from Equinox Science. Public filings describe up to approximately $50 million in remaining development and regulatory milestones and tiered royalties in the high-single-digit to low-double-digit range on applicable sales. EyePoint controls rights outside Greater China, while Betta Pharmaceuticals retains rights in China, Hong Kong, Taiwan and Macau.

These obligations do not destroy the product economics, but they mean gross product revenue will not translate directly into EyePoint operating profit. A realistic valuation must incorporate royalties, manufacturing cost, commercial infrastructure, payer discounts, ongoing post-marketing work and the capital required to launch.

Patent position

EyePoint’s filings describe compound patent protection extending into 2037 and a U.S. DURAVYU insert-formulation patent expected to extend protection into 2043. Additional injector-related applications could potentially extend parts of the estate further. Patent duration is supportive, but commercial exclusivity ultimately depends on claim strength, freedom to operate, regulatory exclusivity, manufacturing know-how and the pace of competing innovation.

13 Legal, Regulatory and Compliance Context

On July 17, 2026, EyePoint entered into a settlement agreement with the U.S. government and the relator in a False Claims Act matter concerning historical sales, marketing, sampling and reimbursement-support practices for DEXYCU, which EyePoint commercialized from 2019 through 2023. The company agreed to pay approximately $4.679 million, plus 4.25% annual interest from January 28, 2026, and an additional $166,500 in relator counsel fees. The Q2 10-Q confirms that the settlement payment was made in full on July 31; the counsel-fee payment remained subject to the separate 60-day deadline described in the agreement.

The EyePoint Form 8-K states that the settlement avoids the uncertainty and expense of litigation and does not constitute an admission of liability by the company. Government releases describe the resolved allegations in stronger terms, including alleged kickbacks through an assurance program and excessive free samples. Readers should preserve that distinction rather than merging the company’s legal characterization with the government’s allegations.

EyePoint also entered into a five-year Corporate Integrity Agreement with the HHS Office of Inspector General. The settlement amount is modest relative to the March 2026 cash balance and does not directly concern DURAVYU clinical efficacy. The longer-term investor issue is the continuing compliance burden: training, monitoring, reporting, governance controls and potential consequences if the company fails to satisfy the agreement.

Why the immediate financial impact is manageable

• The cash payment is small relative to the reported $180.5 million June liquidity balance.
• The matter relates to a historical product commercialized from 2019 to 2023.
• The settlement resolves the covered civil claims conditioned on payment.

Why it still belongs in the investment case

• The Corporate Integrity Agreement runs for five years.
• Commercial launch preparation for DURAVYU will occur under enhanced compliance obligations.
• Compliance failures can create reputational, operational and regulatory consequences.

14 Financial Position: Stronger Than Many Binary Biotechs, but Burn Is High

EyePoint ended the second quarter of 2026 with $180.5 million in cash, cash equivalents and marketable securities, down from $222.5 million at March 31 and $306.1 million at December 31, 2025. Management kept its guidance that the current plan is funded into the fourth quarter of 2027, beyond the 2026 wet-AMD readouts and into the DME Phase 3 period. The runway is strategically useful, but it is a management estimate dependent on trial, manufacturing, launch-readiness and financing assumptions.

Q2 was a high-spend quarter. Revenue was only $0.507 million, compared with $5.333 million in Q2 2025, because historical YUTIQ deferred-revenue recognition had largely run off. R&D expense rose 51% year over year to $83.6 million, G&A increased 20% to $14.2 million and total operating expenses reached $97.9 million. The quarterly operating loss was $97.4 million and net loss was $94.5 million, or $1.09 per basic and diluted share.

The six-month view is more useful than subtracting quarter-end cash balances. During the first half of 2026, EyePoint used $142.9 million of cash in operating activities, versus $115.7 million in the comparable 2025 period. First-half R&D was $155.8 million, total operating expenses were $185.8 million and net loss was $179.3 million. Cash and securities declined partly because marketable securities matured into cash; the cash-flow statement, not the change in the headline liquidity balance, is the better measure of operating consumption.

Spending is concentrated in the four pivotal DURAVYU trials, manufacturing scale-up at Northbridge and commercial preparation. That can make quarter-to-quarter comparisons uneven as trial invoices and manufacturing batches are recognized. It does not change the central conclusion: EyePoint is well enough funded to reach the immediate data, but not funded to commercial self-sufficiency on the current evidence.

No Q2 earnings call was held. EyePoint said it skipped the earnings-related call because the LUGANO topline readout was approaching and plans to provide an update together with those data. That choice does not alter the filed numbers, but it makes the forthcoming clinical release the next likely venue for management’s fuller strategic commentary.

Share count and dilution

The Q2 filing turns dilution from a future risk into a current fact. During the three and six months ended June 30, EyePoint sold 1,429,047 common shares through its ATM at a weighted average price of $14.16, raising approximately $20.2 million gross and about $19.5 million after roughly $0.7 million of issuance costs. During July, it sold another 1,208,718 shares at a weighted average price of $14.44, raising approximately $17.5 million gross before about $0.5 million of costs.

Common shares outstanding rose from 82.83 million at December 31, 2025 to 84.98 million at June 30 and 86.21 million at July 31. This increase reflects ATM issuance, equity compensation and option or employee-plan activity. Another 2.59 million pre-funded warrants were outstanding at June 30 and were included in the loss-per-share denominator. Shareholders also approved 4.9 million additional shares for the 2023 Long-Term Incentive Plan in June, leaving approximately 6.33 million shares available for new awards at quarter-end.

The correct capitalization analysis therefore should not stop at basic common shares. A fully diluted framework needs to consider pre-funded warrants, employee options, restricted units, plan reserves, future financing and the possibility that a positive dataset is followed by a larger strategic capital raise.

15 Ownership, Short Interest and Event-Driven Trading Structure

EyePoint has meaningful specialist and institutional ownership. The 2026 proxy identified holders including Cormorant Asset Management, Suvretta Capital, Federated Hermes, BlackRock and Paradigm Biocapital at or above approximately 5% based on their respective reporting dates. Later filings can show changes—Adage, for example, reported a lower position in a subsequent filing—so ownership snapshots should not be added together as though they all describe the same date.

The 2025 annual report stated that approximately ten shareholders owned about 62% of the company. Concentration can support patient capital and informed biotech sponsorship, but it can also amplify price movement if large holders reduce exposure after data or use strength to rebalance.

Short interest is unusually important

As of June 30, 2026, reported short interest was approximately 15.1 million shares, or about 19% of the public float, with roughly 9.6 days to cover based on the cited provider’s volume measure. Other data services may calculate the percentage differently because they use different float definitions. The practical conclusion is the same: bearish or hedged positioning is high.

High short interest does not prove that shorts are directionally correct. Some positions may hedge options, convertible exposure, sector baskets or event risk. It does mean the stock may react disproportionately to clear data. Strong results can force rapid covering; weak results can validate the short thesis and deepen downside. A mixed readout can create violent two-way trading as the market debates statistical success versus commercial quality.

Positive event mechanics

• Clear Phase 3 success can trigger short covering.
• Two readouts close together may sustain attention and liquidity.
• Specialist ownership can support rapid institutional re-underwriting.
• A credible filing path can broaden the shareholder base.

Negative event mechanics

• Binary failure can produce a gap with limited natural buyers.
• Concentrated holders may rebalance simultaneously.
• Options hedging can magnify intraday volatility.
• Future financing can cap a post-data rally.

What the summer filings actually say, holder by holder

The paragraph above cites the proxy. Four primary documents now say it more precisely, and all four carry the same event date of June 30, 2026. Cormorant Asset Management, LP amended its Schedule 13G on August 14 reporting 7,000,000 shares, 8.35% of the class. BlackRock, Inc. amended on July 28 with 6,430,477 shares, 7.7%. Adage Capital Management, L.P. filed a new Schedule 13G on August 12 with 4,790,792 shares, 5.71%, and Vanguard Capital Management LLC filed on July 31 with 4,223,415 shares, 5.03%. Together those four are roughly 27% of the class on that one date. They should not be added to percentages carrying other dates, which is exactly the mistake the earlier paragraph warns about.

Two Form 4s in August, and only one of them is a trade

On August 18 director Karen L. Zaderej reported buying 10,600 shares at $4.93 under transaction code P, an open-market purchase rather than an award. On August 24 chief financial officer George Elston reported that on August 20 he moved 5,000 shares into a trust for the benefit of his children and 64,953 shares into a grantor-retained annuity trust, at a stated price of zero under codes J and G. Those are estate-planning transfers, not sales: the shares changed the form in which they are held, not the hands that hold them, and reading them as insider selling would be wrong. A provider that scores insider activity on share counts alone can easily make that mistake.

16 Management and Commercial Readiness

EyePoint is led by President and Chief Executive Officer Jay S. Duker, M.D., a retina specialist with direct clinical familiarity with the disease area. George O. Elston serves as Executive Vice President and Chief Financial Officer, and Ramiro Ribeiro, M.D., Ph.D. serves as Chief Medical Officer.

The company has deliberately added launch and scientific leadership ahead of Phase 3 data. Michael Campbell became Chief Commercial Officer in February 2026 after more than three decades in ophthalmology commercialization, including work connected to Lucentis, Xiidra, Beovu and other eye-care franchises. In July 2026, EyePoint appointed retina specialist Tarek S. Hassan, M.D., as Chief Strategic Science Officer to provide guidance across development, potential commercialization and pipeline strategy.

These hires support the interpretation that EyePoint intends to prepare for a U.S. launch rather than wait until after data to build capabilities. They also add cost and equity compensation before regulatory risk has been resolved. Commercial hiring is therefore both a sign of confidence and a capital-allocation commitment.

17 Competitive Landscape After the LUGANO Miss

Wet AMD already has effective anti-VEGF standards, including EYLEA HD and Vabysmo, as well as longer-duration approaches such as Susvimo. DURAVYU therefore needed not only statistical credibility but also a persuasive burden-reduction profile. LUGANO’s 42% reduction supports the differentiation thesis, but the formal efficacy miss raises the bar for LUCIA and for any future regulatory argument.

For the latest competitor context, see the Ocular Therapeutix ($OCUL) Stock Hub.

18 Analyst Opinions and Expectation Risk

Published sell-side targets in July 2026 covered a very wide range, roughly from $20 to the high $60s depending on firm and date, with several recent targets in the $30–$60 range. Data aggregators also reported strongly positive consensus ratings. These figures are opinions, not independently verified intrinsic values, and they are unusually sensitive to assumptions about Phase 3 success, launch timing, penetration, pricing, royalties and dilution.

The dispersion is more informative than the average. It shows that analysts assign very different probabilities and commercial values to DURAVYU. A target built on both studies succeeding cannot be compared directly with a current share price that embeds a meaningful probability of failure. After data, analysts will need to replace probability-weighted assumptions with the actual clinical profile.

Merlintrader does not publish a proprietary price target above. A defensible valuation would require explicit probability-adjusted sales by indication, launch timing, gross-to-net assumptions, Equinox royalties, cost of goods, salesforce investment, post-marketing expense, fully diluted shares and the capital likely required before profitability.

19 Scenario Framework for EYPT After LUGANO

20 Principal Risks and Red Flags

• Failed pivotal primary endpoint: LUGANO is formally negative in its prespecified full-dataset analysis.
• Dependence on ad hoc exclusions: the supportive p=0.0096 result removes nine DURAVYU patients after the primary analysis and may not be accepted as confirmatory evidence.
• LUCIA replication risk: a second miss would materially impair the wet-AMD program.
• Regulatory uncertainty: even a positive LUCIA result may require additional analysis, agency agreement or further evidence.
• Concentration risk: DURAVYU represents most of EyePoint’s forward strategic value.
• Cash burn and dilution: substantial development spending and active ATM use can pressure per-share value, especially after a setback.
• Competitive pressure: established and emerging durable wet-AMD options raise the commercial standard.
• Ocular and implant safety: rare inflammatory, infectious, migration or repeat-dosing events can alter the benefit-risk profile as exposure grows.
• Volatility and crowded positioning: high short interest and catalyst-driven trading can amplify moves in both directions.

21 Merlintrader Monitoring Checklist

• The complete LUGANO BCVA treatment difference, confidence interval and noninferiority margin.
• Causes, timing, sites and adjudication for the nine excluded severe vision-loss cases.
• All prespecified and post hoc sensitivity analyses, including missing-data treatment.
• Treatment-naive versus previously treated outcomes.
• Distribution and timing of supplemental injections, not only averages.
• Detailed inflammation, vasculitis, endophthalmitis, migration and repeat-dose safety tables.
• LUCIA topline timing and whether its prespecified primary endpoint is met cleanly.
• FDA feedback and any revision to the previously contemplated NDA timetable.
• Cash use, ATM activity, operating-plan changes and runway guidance.
• COMO and CAPRI execution in diabetic macular edema.

22 Merlintrader Bottom Line

LUGANO did not prove that DURAVYU lacks clinical activity; it did prove that the first pivotal study failed its prespecified primary statistical test. The 42% treatment-burden reduction, supplement-free rates, small reported anatomical differences and favorable safety language keep a clinically relevant signal alive. The ad hoc p=0.0096 analysis offers a plausible explanation for part of the miss, but it cannot convert a formally negative trial into a positive one.

The investment case is therefore narrower and riskier. LUCIA in Q4 2026 is no longer simply confirmation of an expected win: it is the decisive opportunity to demonstrate clean prespecified efficacy and preserve a credible regulatory path. Until those data and subsequent FDA feedback are available, EYPT should be treated as a high-volatility, evidence-dependent biotech position rather than a de-risked late-stage story.

23 Follow the next EYPT catalyst update

LUGANO and LUCIA can change the EyePoint thesis within a single release. Join the Merlintrader Telegram channel for material biotech updates, catalyst changes and new Stock Hub revisions.